Register for AllyCon 2024
Join us for a three-day experience where patients, caregivers, and advocates unite against colorectal cancer. Register by October 14 for early bird pricing.
Non-Hispanic Black men have the worst colorectal cancer survival rates of any demographic group, and they are less likely than their non-Hispanic White counterparts to get screened.
Researchers are working to understand all of the variables contributing to this disparity so organizations like the Colorectal Cancer Alliance can build programs and interventions that increase screening and save lives.
A new study of more than 300 Black men in Minnesota, Ohio, and Utah provides evidence that greater masculinity barriers to medical care are associated with decreased intent and uptake of screening.
Researchers have long hypothesized that male beliefs about masculinity -- including “being strong,” self-reliance, and preserving heterosexual authority -- may contribute to lower screening rates. These are further complicated by racism and attitudes about screening.
The paper, which Alliance CEO Michael Sapienza co-authored, explains that:
The study also shows that, among participants, being married reduced screening intention. On this point, the study runs contrary to previous research. The authors note that finding may relate to COVID-19 stressors in play when the data were collected and merits further investigation.
Screening is the No. 1 way to prevent colorectal cancer or catch it early, when it’s most treatable. The study is valuable for informing interventions and health promotion studies focused on increasing rates of screening among Black men. However, the authors note the study’s limitations should be considered.
This research was led by Alliance health equity consultant Dr. Charles Rogers, an assistant professor at the University of Utah School of Medicine.
Learn about The Cancer Promise initiative and how political candidates can pledge to support cancer research, prevention, and care policies. Make your voice heard this election.
This bipartisan legislation aims to improve participation in clinical trials by addressing major barriers such as non-medical expenses, trial location accessibility, diverse participation, and financial implications for patients.
The collaboration aims to raise awareness, encourage screening, and help people better understand their risks.